MA30341B1 - Dérivés de benzimidazole - Google Patents

Dérivés de benzimidazole

Info

Publication number
MA30341B1
MA30341B1 MA31302A MA31302A MA30341B1 MA 30341 B1 MA30341 B1 MA 30341B1 MA 31302 A MA31302 A MA 31302A MA 31302 A MA31302 A MA 31302A MA 30341 B1 MA30341 B1 MA 30341B1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA31302A
Other languages
English (en)
Inventor
Marc Gerspacher
Karl Heinz Krawinkler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30341B1 publication Critical patent/MA30341B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Composés de benzimidazole Un composé de formule (I) ou un sel pharmaceutiquement acceptable ou un ester prodrogue de celui-ci : dans laquelle R, X et Y sont tels que décrits dans la description.
MA31302A 2006-03-30 2008-10-17 Dérivés de benzimidazole MA30341B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0606426.5A GB0606426D0 (en) 2006-03-30 2006-03-30 Benzimidazole derivatives

Publications (1)

Publication Number Publication Date
MA30341B1 true MA30341B1 (fr) 2009-04-01

Family

ID=36424926

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31302A MA30341B1 (fr) 2006-03-30 2008-10-17 Dérivés de benzimidazole

Country Status (24)

Country Link
US (1) US20100227889A1 (fr)
EP (1) EP2004629A2 (fr)
JP (1) JP2009531363A (fr)
KR (1) KR20080110769A (fr)
CN (1) CN101400669A (fr)
AR (1) AR060334A1 (fr)
AU (1) AU2007234021B2 (fr)
BR (1) BRPI0710180A2 (fr)
CA (1) CA2644380A1 (fr)
CL (1) CL2007000850A1 (fr)
CR (1) CR10199A (fr)
EC (1) ECSP088781A (fr)
GB (1) GB0606426D0 (fr)
GT (1) GT200800200A (fr)
IL (1) IL193475A0 (fr)
MA (1) MA30341B1 (fr)
MX (1) MX2008012403A (fr)
NO (1) NO20084543L (fr)
PE (1) PE20071149A1 (fr)
RU (1) RU2008142831A (fr)
TN (1) TNSN08369A1 (fr)
TW (1) TW200806647A (fr)
WO (1) WO2007112913A2 (fr)
ZA (1) ZA200806833B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
KR20190141269A (ko) 2007-04-25 2019-12-23 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CN101668532B (zh) 2007-04-25 2014-08-20 赛特克罗公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
CA2797537C (fr) 2010-03-29 2021-11-23 Cytochroma Inc. Utilisation du compose de 25-hydroxyvitamine d pour la reduction des niveaux de la parathyroide
EP2643298A1 (fr) * 2010-11-26 2013-10-02 Leo Pharma A/S Cyclopentylazines substituées en tant que composés casr-actifs
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP4596045A3 (fr) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Procédés de traitement de la vitamine d

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000026430A (ja) * 1998-07-02 2000-01-25 Taisho Pharmaceut Co Ltd ２、５、６−置換ベンズイミダゾール化合物誘導体
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
AU2003286757B2 (en) * 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
EP1964548A1 (fr) * 2007-03-02 2008-09-03 Novartis AG Compositions pharmaceutiques comprenant un agent calcilytique

Also Published As

Publication number Publication date
RU2008142831A (ru) 2010-05-10
PE20071149A1 (es) 2007-12-04
AU2007234021A1 (en) 2007-10-11
GB0606426D0 (en) 2006-05-10
AR060334A1 (es) 2008-06-11
CA2644380A1 (fr) 2007-10-11
EP2004629A2 (fr) 2008-12-24
CL2007000850A1 (es) 2008-03-14
JP2009531363A (ja) 2009-09-03
TW200806647A (en) 2008-02-01
ZA200806833B (en) 2009-05-27
BRPI0710180A2 (pt) 2011-08-09
TNSN08369A1 (en) 2009-12-29
CN101400669A (zh) 2009-04-01
WO2007112913A3 (fr) 2007-12-21
GT200800200A (es) 2008-11-10
IL193475A0 (en) 2009-05-04
NO20084543L (no) 2008-10-21
MX2008012403A (es) 2008-10-07
CR10199A (es) 2008-10-16
KR20080110769A (ko) 2008-12-19
US20100227889A1 (en) 2010-09-09
WO2007112913A2 (fr) 2007-10-11
ECSP088781A (es) 2008-10-31
AU2007234021B2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
MA30341B1 (fr) Dérivés de benzimidazole
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MX2007004699A (es) Derivados de indol y bencimidazol.
MA30652B1 (fr) Composes organiques
MA33528B1 (fr) Derives pyridin-4-yliques
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
MA31988B1 (fr) Derives d'aminopyrazole
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
EA200801381A1 (ru) Производные пиримидина
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA31580B1 (fr) Derives de bicyclolactames substitués
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE519764T1 (de) Spiroindolinon-derivate
TNSN08407A1 (en) Organic compounds
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
MA32151B1 (fr) Derives de 2-aza-bicyclo[2.2.1]heptane
WO2007109578A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
TW200612958A (en) Substituted imidazole derivatives
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
TN2010000038A1 (en) Organic compounds
MA28291A1 (fr) Derives benzimidazole